

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 September 2023 (21.09.2023)



(10) International Publication Number
WO 2023/174569 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/28 (2006.01)

A61K 39/395 (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(21) International Application Number:

PCT/EP2022/079828

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

25 October 2022 (25.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/321,215 18 March 2022 (18.03.2022) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventors: **CHANG, Shao-chun**; ASTRAZENECA PHARMACEUTICALS LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **KURLAND, John**; ASTRAZENECA PHARMACEUTICALS LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **VLAHOVIC, Gordana**; ASTRAZENECA PHARMACEUTICALS LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF TREATING BILIARY TRACT CANCER USING ANTI-PD-L1 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY

(57) Abstract: The disclosure relates to methods for treating biliary tract cancer (BTC) using an anti-PD-L1 antibody in combination with chemotherapy.

